Haihe Biopharma Overview
- Year Founded
-
2011
- Status
-
IPO Registration
- Employees
-
133
- Latest Deal Type
-
IPO
- (Announced)
- Latest Deal Amount
-
$426M
- Investors
-
40
Haihe Biopharma General Information
Description
Developer of oncology drugs designed to provide anti-tumor therapies for cancer patients. The company's technology utilizes lipid self-emulsifying drug delivery and preclinical evaluation platforms, enabling oncology patients to access small molecule inhibitors, oral solutions, anti-tumor therapies, oncology drugs, chemotherapy formulations and pharmaceutical products.
Contact Information
Website
www.haihepharma.comCorporate Office
- No. 865, Zuchongzhi Road
- Pudong New Area
- Shanghai, 201203
- China
Corporate Office
- No. 865, Zuchongzhi Road
- Pudong New Area
- Shanghai, 201203
- China
Haihe Biopharma Timeline
Haihe Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. IPO | 28-May-2026 | $426M | Announced | Clinical Trials - General | ||
| 13. Secondary Transaction - Private | 01-Mar-2026 | Completed | Clinical Trials - General | |||
| 12. Later Stage VC | 01-Dec-2025 | Completed | Clinical Trials - General | |||
| 11. Secondary Transaction - Private | 01-Nov-2023 | Completed | Clinical Trials - General | |||
| 10. Later Stage VC (Series C) | 01-Jun-2023 | Completed | Clinical Trials - General | |||
| 9. IPO | 21-Sep-2021 | Cancelled | Clinical Trials - General | |||
| 8. Later Stage VC (Series B) | 20-Jul-2020 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC | 10-Jul-2020 | Completed | Clinical Trials - General | |||
| 6. Secondary Transaction - Private | 03-Jul-2020 | $147M | Completed | Clinical Trials - General | ||
| 5. Secondary Transaction - Private | 23-Jun-2020 | $147M | Completed | Clinical Trials - General |
Haihe Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 128,343,351 | $0.08 | $1.32 | 1x | $1.32 | 0.96% | ||
| Ordinary | 83,826,637 | $0.08 | $0.08 | 1x | $0.08 | 10.45% |
Haihe Biopharma Comparisons
Industry
Financing
Details
Haihe Biopharma Competitors (12)
One of Haihe Biopharma’s 12 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA |
Haihe Biopharma Patents
Haihe Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2019170063-A1 | Indolizine compounds, preparation method and use thereof | Inactive | 06-Mar-2018 | ||
| WO-2019170055-A1 | Compounds having cdk4/6 kinase inhibitory activity, pharmaceutical composition thereof and use thereof | Inactive | 05-Mar-2018 | ||
| CA-3090439-A1 | Compound having bet inhibitory activity and preparation method and use therefor | Pending | 06-Feb-2018 | ||
| EP-3750885-A1 | Compound having bet inhibitory activity and preparation method and use therefor | Inactive | 06-Feb-2018 | ||
| EP-3750885-A4 | Compound having bet inhibitory activity and preparation method and use therefor | Inactive | 06-Feb-2018 | C07D471/04 |
Haihe Biopharma Signals
Haihe Biopharma Investors (40)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Warburg Pincus | PE/Buyout | Minority | ||
| Deluxe Family Company | Corporation | Minority | ||
| Hangzhou Tigermed Consulting Company | Corporation | Minority | ||
| Ciit Asset Management | Asset Manager | |||
| Hangzhou Lula Asset Management | Growth/Expansion | Minority |
Haihe Biopharma FAQs
-
When was Haihe Biopharma founded?
Haihe Biopharma was founded in 2011.
-
Where is Haihe Biopharma headquartered?
Haihe Biopharma is headquartered in Shanghai, China.
-
What is the size of Haihe Biopharma?
Haihe Biopharma has 133 total employees.
-
What industry is Haihe Biopharma in?
Haihe Biopharma’s primary industry is Drug Discovery.
-
Is Haihe Biopharma a private or public company?
Haihe Biopharma is a Private company.
-
What is Haihe Biopharma’s current revenue?
The current revenue for Haihe Biopharma is .
-
How much funding has Haihe Biopharma raised over time?
Haihe Biopharma has raised $495M.
-
Who are Haihe Biopharma’s investors?
Warburg Pincus, Deluxe Family Company, Hangzhou Tigermed Consulting Company, Ciit Asset Management, and Hangzhou Lula Asset Management are 5 of 40 investors who have invested in Haihe Biopharma.
-
Who are Haihe Biopharma’s competitors?
Pfizer (Vienna), Pfizer Pakistan, Gilead, Merck & Co., and Cardurion are some of the 12 competitors of Haihe Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process